Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

Emily Huschart; Holly Miller; Dana Salzberg; Courtney Campbell; Kristen Beebe; Charlotte Schwalbach; Kyrie Magee; Roberta H Adams; Alexander Ngwube

doi:10.1080/08880018.2020.1829220

Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia

Pediatr Hematol Oncol. 2021 Mar;38(2):154-160. doi: 10.1080/08880018.2020.1829220. Epub 2020 Nov 5.

Authors

Emily Huschart¹, Holly Miller^{1

2}, Dana Salzberg¹, Courtney Campbell¹, Kristen Beebe^{1

2}, Charlotte Schwalbach¹, Kyrie Magee¹, Roberta H Adams^{1

2}, Alexander Ngwube^{1

2}

Affiliations

¹ Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.
² Mayo Clinic Arizona, Phoenix, Arizona, USA.

PMID: 33150833
DOI: 10.1080/08880018.2020.1829220

Abstract

Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.

Keywords: AML; HSCT; azacitidine; prophylactic DLI.

MeSH terms

Adolescent
Antimetabolites, Antineoplastic / pharmacology
Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / pharmacology
Azacitidine / therapeutic use*
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Infant
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / therapy*
Lymphocyte Transfusion / methods*
Male
Transplantation Conditioning / methods*

Substances

Antimetabolites, Antineoplastic
Azacitidine